Multiple myeloma (MM) is a B cell malignancy characterized by the accumulation of clonal plasma cells in the bone marrow (BM) secreting a monoclonal immunoglobulin. Due to the limited success of conventional chemotherapies in MM, intensified high-dose (HD) chemotherapy regimens followed by autologous hematopoietic stem cell transplantation are now widely used.
Peripheral blood has become the main source of hematopoietic stem cells. Besides more rapid engraftment, a lower tumor load has also been reported with peripheral blood stem cell (PBSC) autografts compared to autologous BM. 3, 4 Gene marking studies demonstrated that reinfused tumor cells are involved in causing relapse. 5 Furthermore, in lymphoma the presence of tumor cells in autografts has been correlated with decreased relapse-free survival after transplantation, 6 while in MM the absolute number of plasma cells in autografts achieved borderline significance in predicting relapse-free survival. 7 Thus, minimization of the tumor load in autologous transplants is of major concern. At present, several purging strategies have been established to reduce the amounts of reinfused tumor cells. [8] [9] [10] Influence of the mobilization regimen on the number of circulating tumor cells and on subsequent collection of malignant cells for autografting is still a matter for debate. Brugger et al 11 demonstrated mobilization of tumor cells in patients with solid tumors. In MM, mobilization kinetics of malignant and PBSC have been compared with contradictory results. Lemoli et al 12 found concomitant mobilization of both cell compartments after treatment with HD chemotherapy plus G-CSF. Gazitt et al 13 showed a differential mobilization, with malignant cells reaching peak values at day 5 and 6, thus permitting the collection of a sufficient harvest with reduced numbers of clonotypic cells on the preceding days.
In this report, we used fluorescence activated cell sorting (FACS) analysis for the determination of CD34
+ cells and a quantitative polymerase chain reaction (PCR) assay based on limiting dilutions for calculation of percentages of tumor cells in leukapheresis products (LP) collected on day 1 (LP1) and 2 (LP2) after mobilization of stem cells by HD chemotherapy and G-CSF administration in 16 patients with MM. Furthermore, from six of these patients LP collected on day 5 (LP5) were assessed.
Patients and methods

Patient characteristics
Characteristics of the 16 patients enrolled into the study are shown in Table 1 . Each patient was diagnosed with MM based upon standard criteria. 14 All patients had been included in a phase II study evaluating the efficacy of HDT and PBSCT in the therapy of MM. 15 Patients gave their informed consent regarding the collection of samples for this study. At the time of mobilization, two patients were in complete remission (CR), 11 patients had achieved partial remission (PR) and three patients showed minimal response (MR) according to the EBMT criteria. 16 
PBSC mobilization
Patients were treated with HD cyclophosphamide (HD-CY, seven patients with 7 g/m 2 , five patients with 4 g/m 2 (Asta Medica, Dresden, Germany) ) or in cases of pre-existing heart disease or amyloidosis with ifosfamide/mitoxantrone (Ifo/Mito, four patients, Ifo 4 g/m 2 day 1+2 (Asta Medica) and Mito 10 mg/m 2 day 2+3 (Lederle, Münster, Germany) ) plus G-CSF (Amgen-Roche, München, Germany). G-CSF administration was started at a dose of 300 or 600 g/day 24 h after chemotherapy and continued until PBSC harvesting was completed. PBSC apheresis was initiated when more then 20 CD34
+ cells per l could be identified in PB by direct FACS analysis. If no CD34
+ population appeared, aphereses were started when leukocyte counts reached more than 25 × 10 9 cells per liter and platelets were greater than 80 × 10 9 cells per liter. Harvesting was performed with a CS 3000 (Baxter Deutschland, München, Germany) or a Cobe Spectra (Cobe, Lakewood, CO, USA). For each leukapheresis, 10 l of blood (SVL, small volume) were processed at a flow rate of 50-70 ml/min, or 20 l were collected by a large volume (LVL) procedure. 17 Since the LVL resulted in a two-fold greater number of PBSC, CD34
+ numbers of 10 l harvested were doubled for statistical analysis and calculation of collected CD34
+ cells/kg body weight (BW) per leukapheresis. To support HD chemotherapy with melphalan with or without total body irradiation, an autograft containing more than 2.0 × 10 6
CD34
+ cells/kg BW was considered to be necessary for a successful engraftment. 18, 19 We aimed to achieve a harvest of у6.0 × 10 6 CD34 + cells/kg BW to allow the possibility of double HD treatments with PBSC support and to have one back-up autograft in case relapse treatment became necessary. 20 Interruption of stem cell harvesting between days 2 and 5 was due to a weekend break. PBSC were cryopreserved, as previously described. 21, 22 Patient samples BM aspirates obtained prior to mobilization therapy were used for identification of complementarity determining region 3 (CDR3) of the immunoglobulin heavy chain gene representing a specific marker for each myeloma clone. LP of the 16 patients collected on days 1 and 2, and in six Immunofluorescence analysis 1 × 10 6 MNC of the LP or 20-50 l of whole blood (EDTA) were incubated for 30 min at 4°C with fluorescein isothiocyanate-conjugated anti-CD34 antibody (HPCA-2) obtained from Becton Dickinson (Heidelberg, Germany). Isotype-identical antibodies served as controls. Immunofluorescence analysis was performed using a five-parameter FACSscan (Becton Dickinson) as previously described. 22 
Quantitative assessment of tumor cells and statistical analysis
RNA and DNA extraction, CDR3 consensus PCR, cloning and sequencing of the patient-specific CDR3 regions with the subsequent generation of allele-specific oligonucleotides complementary to the specific CDR3 region were performed as described previously. 23 Quantitative ASO-PCR was carried out essentially as reported. 24 In brief, per aliquot of LP, 2 g of DNA (equivalent to 3.3 × 10 5 cells) was serially diluted in 10- fold steps with placental DNA (Clontech, Palo Alto, CA, USA) and amplified using the patient-specific ASO together with the antisense J H -consensus primer. 25 At each dilution level, 5 or 10 identical PCR reactions were performed simultaneously in a volume of 50 l with 2 g of genomic DNA, 2.5 U AmpliTaq Gold DNA-polymerase (Perkin Elmer, Weiterstadt, Germany), 2 mm MgCl 2 , 5 l GeneAmp 10 × PCR buffer II, 0.2 mm of dNTPs and 0.6 m of each primer.
Furthermore, to validate the quantitative PCR assay, cells from the myeloma cell line U266 were serially diluted in 10-fold steps with cells of a melanoma cell line maintaining a final concentration of 5 × 10 5 cells per tube. After DNA isolation, amplification was also performed in five replicates at each dilution level. Dilutions down to one U266 cell in 5 × 10 5 melanoma cells were assessed. The number of malignant cells in LP was determined by using a maximum likelihood function based upon the Poisson distribution of positive and negative reactions at each sample dilution. The calculation was done by 2 minimization.
Statistical differences between the tumor cell contents, the amounts of stem cells and the proportion of tumor cells per CD34
+ cell at day 1, day 2 and day 5 of leukapheresis, 
Results
Validation of the ASO-PCR assay
The PCR assay used had to be sensitive enough to detect one tumor cell in the PCR tube independent of the number of surrounding normal cells. In order to demonstrate this, dilution series with the myeloma cell line U266 were performed. After 5 × 
Quantitative assessment of tumor and stem cells in LP1 and LP2
In four of 38 LP collected after HD chemotherapy and G-CSF administration, no tumor cells were detectable. The percentages of malignant cells within the remaining 34 LP ranged between 0.0005% and 0.713% (mean 0.0527%). The observed 3-log differences are due to variations from patient to patient. A 1.1-log variation in the percentage of tumor cells was the maximum value seen within one patient. The results of a dilution series of LP1 and LP2 from patient 1 are shown in Figure 2 . When comparing LP1 and LP2 from all 16 patients, no significant differences could be observed with mean percentages of clonotypic cells of 0.0538% vs 0.0448% (P = 0.96). The percentages of CD34
+ stem cells in these LP were in the range from 0.06% to 5.4% (mean 1.41%) reflecting also large interindividual variation as opposed to the relatively small intraindividual differences with mean values of 1.49% vs 1.33% (P = 0.50). Calculating the number of tumor cells per CD34 + cell revealed no significant differences between the two LP either (0.0420 vs 0.0249; P = 0.65). Results of the quantitative PCR and of the immunofluorescence analysis are summarized in Table 2 .
Tumor and stem cell yield in LP5
From six patients entered into the study LP5 was also available due to poor mobilization of CD34 + cells in these patients. The percentages of clonotypic cells in LP on day 5 ranged from 0.0005% to 0.12% (mean 0.0358%) and the level of CD34 + cells was between 0.11% and 0.51% (mean 0.25%). The values obtained and the calculated proportion of tumor cells per CD34
+ cells revealed no significant increases or decreases compared to day 1 of collection (Table 3 ). These results indicate that the CD34
+ and the tumor cell content in PBSC harvests remain fairly constant during the stem cell harvest period (Figure 3) .
Discussion
In the present study, 34 of 38 LP products analyzed contained tumor cells. The calculated range was between 0.0005% and 0.713%. Using ASO-PCR-based methods for the quantitation of tumor cells Vescio et al 3 and Henry et al 4 reported percentages at a level of 0.0005% to 0.35% and 0.001% to 0.62%, respectively. With a different quantitation approach Gazitt et al 13 determined higher numbers of up to 22%, comparable with those obtained by immunophenotypic methods. 7, 12 As the majority of patients with MM relapses after HD therapy and PBSC transplantation, reinfused tumor cells are considered as the possible source of relapse. In order to eradicate or to minimize this possible source of treatment failure, CD34
+ enrichment procedures have been established. 10 Nevertheless, only a certain proportion of patients with MM are eligible for these enrichment procedures because pretreated patients in particular often do not relinquish sufficient hematopoietic stem cells. As published recently, of 97 patients entered into a study for stem cell mobilization, only 41 patients achieved an autograft of more than 5.0 × 10 6 stem cells/kg BW sufficient for CD34 + selection. 20 Furthermore, the question arises of whether minimization of tumor load could be achieved by optimizing the time point of stem cell collection. Our results revealed no significant changes in the quantity of stem cells or tumor cells on days 1, 2 and 5 of the harvesting period. This is in contrast to Gazitt et al 13 who showed a differential mobilization of both cell compartments, permitting the collection of autografts with reduced numbers of tumor cells. Concomitant mobilization of tumor and stem cells has been reported by Lemoli et al. 12 Remarkably, they saw a sharp decline of both cell types during the collection period not confirmed by our results. Whether the collection process per se is responsible for this phenomenon which was not seen in our study remains unresolved.
In summary, our results indicate that LP collected over several days can be combined in order to reach a sufficient amount of hematopoietic stem cells for autografting without increasing the risk of reinfusing significantly higher amounts of tumor cells. Furthermore, these results may be relevant for enrichment procedures in so far as the measured interindividual differences in tumor load and stem cell yield will have a greater influence on the efficacies that these procedures can achieve than the time point of harvesting.
